Author

Autumn F. Burnette

Observed names: A F Burnette, A.F. Burnette, Autumn F Burnette

Institutions: Howard University, Howard University Hospital

Observed institutions: Howard University, Howard University Hospital

OpenAlex ID: A5016434940

Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study

2025 · Njira L. Lugogo, Praveen Akuthota, et al. · Advances in Therapy · 26

Pilot Study of Asthmawin Mobile Iphone App in the Management of Asthma

2017 · Elena R. Reece, Autumn F. Burnette, et al. · Journal of Allergy and Clinical Immunology · 5

Tezepelumab in real-world US patients with severe asthma across phenotypes and underrepresented populations: the phase 4 PASSAGE study

2026 · Njira L Lugogo, Praveen Akuthota, et al. · American Journal of Respiratory and Critical Care Medicine · 3

Correction to: Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study

2025 · Njira L. Lugogo, Praveen Akuthota, et al. · Advances in Therapy · 1

B32-46 Tezepelumab in Diverse Real-World Patients With Severe Asthma Across Different Phenotypes and Underrepresented Populations: Final Results From the US Phase 4 PASSAGE Study

2026 · N L Lugogo, P Akuthota, et al. · American Journal of Respiratory and Critical Care Medicine

B29-17 Albuterol-budesonide Treatment for Acute Airway Obstruction Provides Enhanced Lung Function Improvement Compared to Albuterol in Mild Asthma Irrespective of Baseline Forced Expiratory Volume in One-second (FEV1)

2026 · R A Panettieri, B J Lipworth, et al. · American Journal of Respiratory and Critical Care Medicine

Albuterol-Budesonide Treatment in Acute Airway Obstruction: Patient Selection for the ALTA Study

2025 · P. Akuthota, R.A. Panettieri, et al. · American Journal of Respiratory and Critical Care Medicine

Improvements in Asthma Exacerbations, Lung Function, Asthma Control and Health-related Quality of Life After Tezepelumab Initiation in Patients With Severe Asthma: Interim Results from the US Phase 4 PASSAGE Study

2025 · N.L. Lugogo, P. Akuthota, et al. · American Journal of Respiratory and Critical Care Medicine

Réduction substantielle des exacerbations d’asthme chez des patients asthmatiques sévères après 6 mois de traitement par tézépélumab : résultats intermédiaires de l’étude de phase 4 PASSAGE

2025 · K. Sumino, N.L. Lugogo, et al. · Revue française d'allergologie

Étude de phase 4 visant à évaluer l’efficacité et la tolérance du tézépélumab chez des patients asthmatiques sévères : données démographiques et cliniques à l’inclusion de l’étude PASSAGE

2025 · N.L. Lugogo, K. Sumino, et al. · Revue des Maladies Respiratoires Actualités

A Phase 4, Single-arm, Open-label Study to Evaluate the Effectiveness and Safety of Tezepelumab in Patients With Severe Asthma, Including Underrepresented Racial and Clinical Groups: Initial Baseline Demographics and Clinical Characteristics From the PASSAGE Study

2024 · N.L. Lugogo, K. Sumino, et al.

Rates of Asthma Exacerbations Among Severe, Persistent Asthma Patients in the US Following Event Indicating Uncontrolled Disease

2023 · A.F. Burnette, Y. Chung, et al.

Works count: 12

Citation count: 35

H-index: 3

I10-index: 1